A light-activated metal complex targets both DNA and RNA in a fluorescent in vitro transcription and translation assay

ChemBioChem

Volumn 15, Issue 4, 2014, Pages 507-511

  Heidary, David K ^a   Glazer, Edith C ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

cancer; cisplatin; drug discovery; high throughput screening; ruthenium

Indexed keywords

ALPHA AMANITIN; ANTINEOPLASTIC METAL COMPLEX; CISPLATIN; CYCLOHEXIMIDE; DACTINOMYCIN; DNA; FLUOROURACIL; IMATINIB; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; RNA; RUTHENIUM COMPLEX; VORINOSTAT;

ARTICLE; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DNA DAMAGE; DRUG DETERMINATION; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG TARGETING; FEMALE; FLUORESCENCE ANALYSIS; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC 50; IN VITRO TRANSCRIPTION AND TRANSLATION ASSAY; PRIORITY JOURNAL;

CANCER; CISPLATIN; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING; RUTHENIUM;

CELL-FREE SYSTEM; COORDINATION COMPLEXES; DNA; DNA DAMAGE; GREEN FLUORESCENT PROTEINS; HELA CELLS; HUMANS; PROTEIN BIOSYNTHESIS; RNA, MESSENGER; RUTHENIUM; TRANSCRIPTION, GENETIC;

EID: 84896736882     PISSN: 14394227     EISSN: 14397633     Source Type: Journal    
DOI: 10.1002/cbic.201300681     Document Type: Article

References (41)

1. L. Kelland, Nat. Rev. Cancer 2007, 7, 573-584.
2. S. R. McWhinney, R. M. Goldberg, H. L. McLeod, Mol. Cancer Ther. 2009, 8, 10-16.
3. B. S. Howerton, D. K. Heidary, E. C. Glazer, J. Am. Chem. Soc. 2012, 134, 8324-8327.
4. E. Wachter, D. K. Heidary, B. S. Howerton, S. Parkin, E. C. Glazer, Chem. Commun. 2012, 48, 9649-9651.
5. F. Katzen, G. Chang, W. Kudlicki, Trends Biotechnol. 2005, 23, 150-156.
6. E. D. Carlson, R. Gan, C. E. Hodgman, M. C. Jewett, Biotechnol. Adv. 2012, 30, 1185-1194.
7. C. J. Murray, R. Baliga, Curr. Opin. Chem. Biol. 2013, 17, 420-426.
8. K. E. Berry, B. Peng, D. Koditek, D. Beeman, N. Pagratis, J. K. Perry, J. Parrish, W. D. Zhong, J. A. Doudna, I. H. Shih, J. Biomol. Screening 2011, 16, 211-220
9. O. Novac, A. S. Guenier, J. Pelletier, Nucleic Acids Res. 2004, 32, 902-915. There are also reports of coupled IVTT assays used in drug screening for antibiotics that inhibit translation; see
10. W. A. Greenberg, E. S. Priestley, P. S. Sears, P. B. Alper, C. Rosenbohm, M. Hendrix, S. C. Hung, C. H. Wong, J. Am. Chem. Soc. 1999, 121, 6527-6541
11. C. Fyfe, J. A. Sutcliffe, T. H. Grossman, J. Microbiol. Methods 2012, 90, 256-261. The selectivity of an agent for bacterial versus eukaryotic targets can be determined by comparing IVTT in bacterial and eukaryotic lysates; see
12. L. S. McCoy, K. D. Roberts, R. L. Nation, P. E. Thompson, T. Velkov, J. Li, Y. Tor, ChemBioChem 2013, 14, 2083-2086. In this reference, the distinction is drawn between inhibition of translation and mistranslation, which cannot be distinguished by an assay dependent on protein activity; accordingly, the authors describe the inhibition as "translation interference".
13. T. G. Obrig, W. J. Culp, W. L. McKeehan, B. Hardesty, J. Biol. Chem. 1971, 246, 174-181
14. T. Schneider-Poetsch, J. Ju, D. E. Eyler, Y. Dang, S. Bhat, W. C. Merrick, R. Green, B. Shen, J. O. Liu, Nat. Chem. Biol. 2010, 6, 209-217.
15. G. L. Cohen, W. R. Bauer, J. K. Barton, S. J. Lippard, Science 1979, 203, 1014-1016
16. M. V. Keck, J. Chem. Educ. 2000, 77, 1471-1473.
17. A recent PCR-based assay showed similar discrepancies between the potencies obtained from the functional assay compared to gel-shift assays. See, J. Wang, J. Newman Jr., S. L. Higgins, K. M. Brewer, B. S. Winkel, K. J. Brewer, Angew. Chem. Int. Ed. 2013, 52, 1262-1265
18. Angew. Chem. 2013, 125, 1300-1303.
19. A. A. Hostetter, M. F. Osborn, V. J. DeRose, ACS Chem. Biol. 2012, 7, 218-225.
20. C. Cullinane, S. J. Mazur, J. M. Essigmann, D. R. Phillips, V. A. Bohr, Biochemistry 1999, 38, 6204-6212
21. P. Vichi, F. Coin, J.-P. Renaud, W. Vermeulen, J. H. J. Hoeijmakers, D. Moras, J.-M. Egly, EMBO J. 1997, 16, 7444-7456
22. R. C. Todd, S. J. Lippard, Metallomics 2009, 1, 280-291. However, our results support other findings that a reduction in transcript level does not necessarily lead to a significant reduction in protein biosynthesis.
23. M. C. Shoshan, S. Linder, Expert Opin. Drug Metab. Toxicol. 2008, 4, 273-280
24. G. K. Dy, A. A. Adjei, Ca-Cancer J. Clin. 2013, 63, 249-279.
25. M. M. Gottesman, Annu. Rev. Med. 2002, 53, 615-627.
26. D. M. Molina, R. Jafari, M. Ignatushchenko, T. Seki, E. A. Larsson, C. Dan, L. Sreekumar, Y. H. Cao, P. Nordlund, Science 2013, 341, 84-87.
27. M. A. Fuertes, C. Alonso, J. M. Perez, Chem. Rev. 2003, 103, 645-662.
28. M. J. Banker, T. H. Clark, Curr. Drug Metab. 2008, 9, 854-859.
29. http://www.fda.gov/downloads/ICECI/Inspections/IOM/UCM135835.pdf.
30. A. R. Timerbaev, C. G. Hartinger, S. S. Aleksenko, B. K. Keppler, Chem. Rev. 2006, 106, 2224-2248.
31. F. Cervantes-Gomez, R. Nimmanapalli, V. Gandhi, Cancer Res. 2009, 69, 3947-3954.
32. D. A. Bushnell, P. Cramer, R. D. Kornberg, Proc. Natl. Acad. Sci. USA 2002, 99, 1218-1222
33. F. Brueckner, P. Cramer, Nat. Struct. Mol. Biol. 2008, 15, 811-818
34. O. Bensaude, Transcription 2011, 2, 103-108.
35. S. P. Davies, H. Reddy, M. Caivano, P. Cohen, Biochem. J. 2000, 351, 95-105.
36. Creatine phosphokinase is commonly used in ATP regeneration systems for IVTT; see, G. Witherell, in Current Protocols in Cell Biology (Eds.:, J. S. Bonifacino, M. Dasso, J. Lippincott-Schwartz, J. B. Harford, K. M. Yamada,), Wiley, 2001, Chapter 11, Unit 11.8.
37. M. M. Jennerwein, A. Eastman, Nucleic Acids Res. 1991, 19, 6209-6214.
38. J. M. Woynarowski, W. G. Chapman, C. Napier, M. C. S. Herzig, P. Juniewicz, Mol. Pharmacol. 1998, 54, 770-777.
39. R. K. Saiki, D. H. Gelfand, S. Stoffel, S. J. Scharf, R. Higuchi, G. T. Horn, K. B. Mullis, H. A. Erlich, Science 1988, 239, 487-491.
40. K. E. Sandman, S. S. Marla, G. Zlokarnik, S. J. Lippard, Chem. Biol. 1999, 6, 541-551.
41. W. H. Ang, M. Myint, S. J. Lippard, J. Am. Chem. Soc. 2010, 132, 7429-7435.